Kwality Pharmaceuticals cash flow

Latest FY23
Cash from operations
₹42.2cr−33.1% on FY22
Capital spending
₹47.7cr−13.6% on FY22
Free cash flow
−₹5.5cr₹7.9 cr in FY22
Cash from financing
₹1.0cr−82.4% on FY22
₹ crore except per share
Tap a line for its trendFY24Mar 2024FY23Mar 2023FY22Mar 2022
Adjustments to reconcile profit — non-cash items
—14.910.6
Changes in working capital
—−33.0−36.0
Cash from operating activities
31.525.8162
—48.3104
—42.263.1
Cash from investing activities
29.847.755.2
4.11.90.0
−26.4−48.4−63.0
Cash from financing activities
4.1—14.4
11.37.012.3
10.26.02.9
−17.41.05.7
−0.8−5.35.7
Reference items
66.660.3172
21.7%24.0%37.7%
—−5.57.9
——₹7.62
——0.53×
10.26.02.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

KPL₹3,696.70

Kwality Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
View
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation10.614.9—
Changes in Working Capital
+ Inventories-36.0-33.0—
Cash from Operating Activities
Profit Before Tax (per I/S)161.725.831.5
Cash from Operations (pre-tax)104.448.3—
Cash from Operating Activities63.142.2—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)55.247.729.8
+ Disp of Fixed Assets0.01.94.1
Cash from Investing Activities-63.0-48.4-26.4
Cash from Financing Activities
+ Proceeds from Borrowings14.4—4.1
+ Repayment of Borrowings12.37.011.3
+ Interest Paid2.96.010.2
Cash from Financing Activities5.71.0-17.4
Net Changes in Cash5.7-5.3-0.8
Reference Items
EBITDA171.760.366.6
EBITDA Margin %37.6524.0221.69
Free Cash Flow (CFO − Capex)7.9-5.5—
Free Cash Flow per Basic Share7.62——
Cash Flow to Net Income0.53——
Cash Paid for Interest2.96.010.2
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.